

Product datasheet for TL319110V

OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200
Rockville, MD 20850, US
Phone: +1-888-267-4436
https://www.origene.com
techsupport@origene.com
EU: info-de@origene.com
CN: techsupport@origene.cn

MLLT11 Human shRNA Lentiviral Particle (Locus ID 10962)

Product data:

Product Type: shRNA Lentiviral Particles

Locus ID: 10962

Synonyms: AFIQ

Vector: pGFP-C-shLenti (TR30023)

Format: Lentiviral particles

Components: MLLT11 - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble

control), 0.5 ml each, >10^7 TU/ml.

RefSeq: NM_006818, NM_006818.1, NM_006818.2, NM_006818.3, BC022448, BC022448.1, BC006471,

BC007079, BC008445, BC009624, BC019253, BC021703, BC032996, NM_006818.4

UniProt ID: Q13015

Summary: The gene variously symbolized ALL1, HRX, or MLL located on 11q23 has been demonstrated to be

fused with a number of translocation partners in cases of leukemia. t(1;11)(q21;q23)

translocations that fused the MLL gene to a gene on chromosomal band 1q21 in 2 infants with acute myelomonocytic leukemia have been demonstrated. The N-terminal portion of the MLL gene is critical for leukemogenesis in translocations involving band 11q23. This gene encodes 90 amino acids. It was found to be highly expressed in the thymus but not in peripheral lymphoid tissues. In contrast to its restricted distribution in normal hematopoietic tissue, this

gene was expressed in all leukemic cell lines tested. [provided by RefSeq, Jul 2008]

shRNA Design: These shRNA constructs were designed against multiple splice variants at this gene locus. To

be certain that your variant of interest is targeted, please contact <u>techsupport@origene.com</u>. If you need a special design or shRNA sequence, please utilize our <u>custom shRNA service</u>.





Performance Guaranteed: OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

> For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).